Clinical Trial Update: Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial update evaluating LB-100 in combination with doxorubicin versus doxorubicin alone as first-line treatment for advanced soft-tissue sar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft-tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• LB-100 (LB-100)

Snippet

Sponsor: Grupo Espanol de Investigacion en Sarcomas | Conditions: Advanced Soft-tissue Sarcoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING